Next Article in Journal
Revealing the Intrinsic Correlation between Cu Scales and Free Radical Chain Reactions in the Regulation of Catalytic Behaviour
Previous Article in Journal
Synthesis of an Ethylenediaminetetraacetic Acid-like Ligand Based on Sucrose Scaffold and Complexation and Proton Relaxivity Studies of Its Gadolinium(III) Complex in Solution
Previous Article in Special Issue
A New Wound-Healing Tool Based on Glycyrrhiza glabra Extract-Loaded Ufasomes on Spanish Broom Dressings
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Review

Liposome-Assisted Drug Delivery in the Treatment of Multiple Sclerosis

by
Giuliana Greco
1,2 and
Maria Grazia Sarpietro
2,3,*
1
Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy
2
NANOMED-Research Center on Nanomedicine and Pharmaceutical Nanotechnology, University of Catania, 95125 Catania, Italy
3
Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy
*
Author to whom correspondence should be addressed.
Molecules 2024, 29(19), 4689; https://doi.org/10.3390/molecules29194689
Submission received: 8 July 2024 / Revised: 27 September 2024 / Accepted: 28 September 2024 / Published: 3 October 2024
(This article belongs to the Special Issue Recent Advances in (Phospho)lipid-Based Drug Delivery Nanosystems)

Abstract

Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the nervous system that leads to neurological dysfunctions and severe disabilities. It is worth noting that conventional pharmacotherapy is poorly selective and causes toxicity problems and several systemic side effects. Thus, there is a need to develop new approaches to this medical challenge. The use of nanocarriers for drug delivery represents a good strategy to overcome several issues such as high therapeutic drug doses with side effects, such as diarrhea, nausea, and abdominal pain, and drug degradation processes; in addition, nanocarriers can provide controlled and targeted drug release. This review describes the application of liposomes for the delivery of pharmaceutical actives to target MS. Firstly, MS is explained. Then, liposomes are described along with their preparation, characterization, and stability. The literature about the use of liposomes for the treatment of MS is then analyzed.
Keywords: multiple sclerosis; BBB; EAE models; nanocarriers; liposomes; drug delivery multiple sclerosis; BBB; EAE models; nanocarriers; liposomes; drug delivery

Share and Cite

MDPI and ACS Style

Greco, G.; Sarpietro, M.G. Liposome-Assisted Drug Delivery in the Treatment of Multiple Sclerosis. Molecules 2024, 29, 4689. https://doi.org/10.3390/molecules29194689

AMA Style

Greco G, Sarpietro MG. Liposome-Assisted Drug Delivery in the Treatment of Multiple Sclerosis. Molecules. 2024; 29(19):4689. https://doi.org/10.3390/molecules29194689

Chicago/Turabian Style

Greco, Giuliana, and Maria Grazia Sarpietro. 2024. "Liposome-Assisted Drug Delivery in the Treatment of Multiple Sclerosis" Molecules 29, no. 19: 4689. https://doi.org/10.3390/molecules29194689

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop